LACE+ and MRS Score Readmission Rate Assessment

Overview

A study to demonstrate that the LACE+ score in non-inferior to the medication risk score when predicting 30-day readmission post hospital discharge.

Full Title of Study: “Comparing the Predictive Strength of the LACE+ Index With the MedWise Rise Score on Hospital Readmission Rates: a Non-inferiority Observational Study”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: April 24, 2021

Detailed Description

The objective of this study is evaluate a program that provides transition of care services to a local Tucson hospital involving activities designed to reduce 30 day post hospital discharge readmission rates. The organization has had a fee for service contract with this hospital since 2017 to provide pharmacist delivered transition of care services. The organization collects internal tracking outcome data as part of the contract deliverable and is required to report it to the hospital once per month. The investigators look to assess LACE+ and medication risk scores to learn if there is an association with the 30 day post hospital discharge readmission rate post pharmacist intervention. The outcomes will not be generalizable and will be reported back to the hospital client to demonstrate value added.

Interventions

  • Other: Pharmacist transition of care consultation
    • Pharmacist-delivered comprehensive medication review

Arms, Groups and Cohorts

  • Readmitted
    • Patients that were readmitted within 30 days post hospital discharge
  • Not readmitted
    • Patients that were not readmitted within 30 days post hospital discharge

Clinical Trial Outcome Measures

Primary Measures

  • Readmission
    • Time Frame: 2018 – 2019
    • Readmission within 30-days post hospital discharge

Participating in This Clinical Trial

Inclusion Criteria

  • Those referred to receive transition of care services between January 2018 to December 2019 and were discharged on 10 or more medications.

Exclusion Criteria

  • 89 years or older

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 88 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Tabula Rasa HealthCare
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jenny Bingham, Director, Ambulatory Care Residency Programs & Research – Tabula Rasa HealthCare
  • Overall Official(s)
    • Jennifer Bingham, PharmD, Principal Investigator, Tabula Rasa HealthCare
  • Overall Contact(s)
    • Jennifer Bingham, PharmD, 520-955-8587, jbingham@trhc.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.